Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4425 - Simultaneous resection of colorectal primary tumor and liver metastasis after neoadjuvant therapy: A propensity score matching analysis

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Surgical Oncology

Tumour Site

Colon and Rectal Cancer

Presenters

Ye Xu

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

Y. Xu

Author affiliations

  • Department Of Colorectal Cancer, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
More

Resources

Abstract 4425

Background

Considering the surgical safety and presentation of perioperative complications, simultaneous resection of colorectal cancer and liver metastasis after neoadjuvant treatment is not regularly conducted in many centers. Herein, we assessed and compared the surgical safety and incidences of postoperative complications in patients with and without neoadjuvant treatment.

Methods

A total of 257 patients who underwent simultaneous resection were included in this single-center, retrospective study. Comparison of the short-term outcomes was performed after propensity score adjustment.

Results

No postoperative death occurred. After matching, the differences from colorectal cancer and liver metastasis were well-balanced. The median operative time, and blood loss and intraoperative transfusion rates did not differ between Group A (without neoadjuvant treatment) and Group B. The morbidity (Group A vs. Group B, 15.4% vs. 19.2%, p = 0.420), and Clavien-Dindo grade of complications (p = 0.632) were also similar. No difference was found when the complications were divided according to the origin (general, colorectal and hepatic). The length of the hospital stays also did not differ between the groups. Ratios of patients with the elevation of some important blood indices related to liver function did not differ, and there was no increase in the number of patients with delayed adjuvant treatment after surgery in Group B.

Conclusions

Simultaneous resection after neoadjuvant treatment was found to be comparably safe. It did not increase morbidity and influence subsequent adjuvant treatment, and may be a treatment option for patients with synchronous liver metastasis.

Clinical trial identification

Legal entity responsible for the study

Fudan University Shanghai Cancer Center.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.